Imaging Skin Changes in Atopic Dermatitis Patients Treated With Nemolizumab
Studies skin changes with a scanning imaging method in adults with atopic dermatitis on nemolizumab.
Plain-language title generated from the registry record
Registry title: Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab
Key facts
- Where
- Romans-Sur-Isere, FranceSee the site
Where in France
- Hopitaux Drome NordRomans-Sur-Isere, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hôpitaux Drôme Nord
- Trial code
- NCT07730788
- Record updated
- 28 July 2026
- Original description
Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic Dermatitis Index (SCORAD) scores, with a risk of intra-observer variations. Nemolizumab is a a humanised anti-IL-31 monoclonal antibody that has proven to be effective and well-tolerated for the treatment of patients with moderate-to-severe AD. Reflectance confocal microscopy (RCM) is a noninvasive procedure that allows to evaluate epidermis and papillary dermis at a cellular level. RCM allows skin structural and inflammatory parameters evaluation.Read full original descriptionShow less
Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab
Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic Dermatitis Index (SCORAD) scores, with a risk of intra-observer variations. Nemolizumab is a a humanised anti-IL-31 monoclonal antibody that has proven to be effective and well-tolerated for the treatment of patients with moderate-to-severe AD. Reflectance confocal microscopy (RCM) is a noninvasive procedure that allows to evaluate epidermis and papillary dermis at a cellular level. RCM allows skin structural and inflammatory parameters evaluation.
The aim of this study is to evaluate by RCM skin modifications of AD patients treated with nemolizumab.
Inclusion: Patients aged 18 years and older; Patients with moderate-to-severe Atopic Dermatitis who require systemic treatment with nemolizumab; Patients affiliated with or entitled to a social security scheme; Patients capable of giving informed consent; Patients who have received informed information about the study and have co-signed an informed consent form for participation in the study, along with the investigator.
Exclusion: Patients with a severe concomitant disease that, in the investigator's opinion, would negatively affect participation in the study; Patients with an uncontrolled chronic disease that may require corticosteroid courses/treatment; Patients who refuse to participate in the study and legally incapacitated adults.